Skip to content

Home Search Authors Pakistan News Saved

SciRah

SciRah does not host or store research papers. Results come live from free, official scholarly APIs, and every paper links back to its original source.

Data sources

OpenAlex
Semantic Scholar
Crossref
CORE
arXiv
PubMed

Privacy policy Terms of service

Chul Kim · SciRah

Researcher profile · Semantic Scholar

Chul Kim

Share profile

Chul Kim — researcher profile on SciRah

h-index: 22
Works: 81
Citations: 2,962

Most-cited papers

The Strength of Association Between Surrogate End Points and Survival in Oncology: A Systematic Review of Trial-Level Meta-analyses.
V. Prasad, Chul Kim, Mauricio Burotto, A. Vandross
2015JAMA Internal Medicine388 citations Open access
Semantic Scholar
Pembrolizumab in patients with thymic carcinoma: a single-arm, single-centre, phase 2 study
G. Giaccone, Chul Kim, Jillian Thompson, C. McGuire +10 more
2018The Lancet Oncology385 citations Open access
Semantic Scholar
Cancer Drugs Approved on the Basis of a Surrogate End Point and Subsequent Overall Survival: An Analysis of 5 Years of US Food and Drug Administration Approvals.
Chul Kim, V. Prasad
2015JAMA Internal Medicine342 citations
Semantic Scholar
Safety and Efficacy of Immune Checkpoint Inhibitor Therapy in Patients With HIV Infection and Advanced-Stage Cancer: A Systematic Review.
Michael R. Cook, Chul Kim
2019JAMA Oncology195 citations
Semantic Scholar
Clonal Evolution and Heterogeneity of Osimertinib Acquired Resistance Mechanisms in EGFR Mutant Lung Cancer
N. Roper, Anna L. Brown, Jun S. Wei, S. Pack +27 more
2020Cell Reports Medicine180 citations Open access
Semantic Scholar
Characterization of KRAS Mutation Subtypes in Non–small Cell Lung Cancer
Julia Judd, N. Abdel Karim, H. Khan, A. Naqash +18 more
2021Molecular Cancer Therapeutics171 citations Open access
Semantic Scholar
Strength of Validation for Surrogate End Points Used in the US Food and Drug Administration’s Approval of Oncology Drugs
Chul Kim, V. Prasad
2016Mayo Clinic proceedings121 citations Open access
Semantic Scholar
Safety and efficacy of immune checkpoint inhibitors (ICIs) in cancer patients with HIV, hepatitis B, or hepatitis C viral infection
Neil J. Shah, Ghassan Al-Shbool, M. Blackburn, Michael R. Cook +7 more
2019Journal of Immunotherapy for Cancer111 citations Open access
Semantic Scholar
Role of Local Ablative Therapy in Patients with Oligometastatic and Oligoprogressive Non–Small Cell Lung Cancer
Chul Kim, C. Hoang, A. Kesarwala, D. Schrump +2 more
2017Journal of Thoracic Oncology97 citations Open access
Semantic Scholar
Phase I study of the 177Lu-DOTA0-Tyr3-Octreotate (lutathera) in combination with nivolumab in patients with neuroendocrine tumors of the lung
Chul Kim, Stephen V. Liu, D. Subramaniam, T. Torres +3 more
2020Journal for ImmunoTherapy of Cancer86 citations Open access
Semantic Scholar
Nivolumab, anti-programmed death-1 (PD-1) monoclonal antibody immunotherapy: Role in advanced cancers
A. Rajan, Chul Kim, C. Heery, U. Guha +1 more
2016Human Vaccines & Immunotherapeutics83 citations Open access
Semantic Scholar
Tarloxotinib is a hypoxia-activated pan-HER kinase inhibitor active against a broad range of HER-family oncogenes
A. Estrada-Bernal, A. Le, Andrea E. Doak, Vijaya G. Tirunagaru +7 more
2020Clinical Cancer Research73 citations Open access
Semantic Scholar
DURABLE RESPONSE IN PATIENTS WITH THYMIC CARCINOMA TREATED WITH PEMBROLIZUMAB AFTER PROLONGED FOLLOW-UP.
G. Giaccone, Chul Kim
2020Journal of Thoracic Oncology68 citations Open access
Semantic Scholar
MEK inhibitors under development for treatment of non-small-cell lung cancer
Chul Kim, G. Giaccone
2018Expert Opinion on Investigational Drugs68 citations
Semantic Scholar
Whole-exome sequencing reveals germline-mutated small cell lung cancer subtype with favorable response to DNA repair–targeted therapies
C. Tlemsani, N. Takahashi, L. Pongor, Vinodh N. Rajapakse +21 more
2021Science Translational Medicine54 citations Open access
Semantic Scholar
Immune checkpoint inhibitor use and tuberculosis: a systematic review of the literature.
Jacob Zaemes, Chul Kim
2020European Journal of Cancer53 citations
Semantic Scholar
Real-world survival outcomes with immune checkpoint inhibitors in large-cell neuroendocrine tumors of lung
E. Dudnik, S. Kareff, M. Moskovitz, Chul Kim +9 more
2021Journal for ImmunoTherapy of Cancer48 citations Open access
Semantic Scholar
Metastatic lymphoepithelioma-like carcinoma of the lung treated with nivolumab: a case report and focused review of literature.
Chul Kim, A. Rajan, P. Debrito, G. Giaccone
2016Translational Lung Cancer Research39 citations Open access
Semantic Scholar
Rethinking the Optimal Duration of Immune Checkpoint Inhibitors in Non-small Cell Lung Cancer Throughout the COVID-19 Pandemic
A. Friedlaender, Chul Kim, A. Addeo
2020Frontiers in Oncology33 citations Open access
Semantic Scholar
The Effects of HER2 Alterations in EGFR Mutant Non-small Cell Lung Cancer.
M. Nagasaka, Vijendra Singh, Y. Baca, A. Sukari +16 more
2021Clinical Lung Cancer31 citations Open access
Semantic Scholar
Precision oncology in non-small-cell lung cancer: opportunities and challenges
Chul Kim, G. Giaccone
2018Nature Reviews Clinical Oncology27 citations
Semantic Scholar
Hepatoid adenocarcinoma of the lung metastasizing to the tonsil.
L. Valle, Joel Thomas, Chul Kim, E. Szabo +3 more
2017Molecular and clinical oncology23 citations Open access
Semantic Scholar
A Systematic Review and Meta-Analysis of Clinical Characteristics and Outcomes in Patients With Lung Cancer with Coronavirus Disease 2019
M. Peravali, I. Joshi, Jaeil Ahn, Chul Kim
2021JTO Clinical and Research Reports22 citations Open access
Semantic Scholar
Immune Checkpoint Inhibitor-induced Fanconi Syndrome
S. Farid, Hira Latif, C. Nilubol, Chul Kim
2020Cureus18 citations Open access
Semantic Scholar
Pembrolizumab in patients with recurrent thymic carcinoma: Results of a phase II study.
G. Giaccone, Jillian Thompson, C. McGuire, M. Manning +7 more
201717 citations
Semantic Scholar
Oral Chemotherapy for Treatment of Lung Cancer
Sushma Jonna, J. Reuss, Chul Kim, Stephen V. Liu
2020Frontiers in Oncology14 citations Open access
Semantic Scholar
Combined Inhibition of EGFR and VEGF Pathways in Patients with EGFR-Mutated Non-Small Cell Lung Cancer: A Systematic Review and Meta-Analysis
M. Peravali, Haijun Wang, Chul Kim, I. Veytsman
2020Current Oncology Reports14 citations
Semantic Scholar
Impact of Baseline Clinical Biomarkers on Treatment Outcomes in Patients With Advanced NSCLC Receiving First-line Pembrolizumab-Based Therapy.
I. Joshi, M. Peravali, X. Geng, S. Rao +5 more
2022Clinical Lung Cancer13 citations
Semantic Scholar
Molecular characterization of Kita-Kyushu lung cancer antigen (KK-LC-1) expressing carcinomas
R. Hsu, Y. Baca, J. Xiu, Rongfu Wang +9 more
2021OncoTarget13 citations Open access
Semantic Scholar
Role of Anti-EGFR Targeted Therapies in Stage III Locally Advanced Non-small Cell Lung Cancer: Give or Not to Give?
Sanjal H. Desai, Chul Kim, I. Veytsman
2019Current Oncology Reports13 citations
Semantic Scholar
Genomic and immunologic characterization of large-cell neuroendocrine carcinoma of the lung.
Chul Kim, J. McGrath, J. Xiu, M. Nagasaka +11 more
2021Journal of Clinical Oncology12 citations
Semantic Scholar
Immunotherapy utilization among patients with metastatic NSCLC: impact of comorbidities
Dongyu Zhang, Tina D. Tailor, Chul Kim, M. Atkins +2 more
2021Journal of immunotherapy10 citations Open access
Semantic Scholar
Safety and Efficacy of First-Line Pembrolizumab in Black Patients with Metastatic Non-Small-Cell Lung Cancer.
M. Peravali, Jaeil Ahn, Kevin Chen, S. Rao +3 more
2021The Oncologist10 citations Open access
Semantic Scholar
Longitudinal Monitoring of EGFR and PIK3CA Mutations by Saliva-Based EFIRM in Advanced NSCLC Patients With Local Ablative Therapy and Osimertinib Treatment: Two Case Reports
Ning Li, U. Guha, Chul Kim, L. Ye +5 more
2020Frontiers in Oncology10 citations Open access
Semantic Scholar
Thymic epithelial tumors and metastasis to the brain: a case series and systematic review.
H. Gharwan, Chul Kim, Anish Thomas, Arlene W. Berman +4 more
2017Translational Lung Cancer Research10 citations Open access
Semantic Scholar
OA18.02 Evaluation of a Modified Dosing Regimen (2-Weeks on/1-Week off) of Sunitinib as Part of a Phase II Trial in Thymic Carcinoma
A. Rajan, Chul Kim, U. Guha, E. Szabo +8 more
201710 citations Open access
Semantic Scholar
Divergent RET- and BRAF-Mediated Resistance to Osimertinib in EGFR-Mutant NSCLC: A Case Report.
M. Rehman, Chul Kim, J. Reuss, L. Kiedrowski +2 more
2021JCO Precision Oncology9 citations
Semantic Scholar
Lessons learned from BATTLE-2 in the war on cancer: the use of Bayesian method in clinical trial design.
Chul Kim, G. Giaccone
2016Annals of Translational Medicine9 citations Open access
Semantic Scholar
EML4-ALK Rearrangement as a Mechanism of Resistance to Osimertinib in Metastatic Lung Adenocarcinoma: A Case Report
Xinyu von Buttlar, J. Reuss, Stephen V. Liu, Chul Kim
2021JTO Clinical and Research Reports7 citations Open access
Semantic Scholar
Current Landscape of Immunotherapy Trials Involving the Programmed Cell Death Protein 1/Programmed Death-Ligand 1 Axis in Intrathoracic Tumors
S. Kareff, S. Samtani, Mauricio Burotto, V. Prasad +1 more
2021JTO Clinical and Research Reports7 citations Open access
Semantic Scholar
Real-world outcomes of underrepresented patient populations treated with immune checkpoint inhibitors (ICIs): African American descent, poor ECOG performance status, and chronic viral infections.
Neil J. Shah, M. Blackburn, Michael R. Cook, A. Belouali +7 more
2019Journal of Clinical Oncology7 citations
Semantic Scholar
P2.12-03 Phase I/II Trial Of 177Lu-DOTA0-Tyr3-Octreotate (Lutathera) And Nivolumab for Patients with Extensive-Stage Small Cell Lung Cancer (ES-SCLC)
Chul Kim, Deepa S. Subramaniam, Stephen V. Liu, G. Giaccone
2018Journal of Thoracic Oncology7 citations Open access
Semantic Scholar
Local ablative therapy (LAT) for oligoprogressive, EGFR-mutant, non-small cell lung cancer (NSCLC) after treatment with osimertinib.
Chul Kim, N. Roper, C. Hoang, Laura Wisch +16 more
20177 citations
Semantic Scholar
Characterization of KRAS mutations (mt) in non-small cell lung cancer (NSCLC).
Stephen V. Liu, A. Vanderwalde, H. Mamdani, L. Raez +15 more
20205 citations
Semantic Scholar
Abstract CT106: Local ablative therapy for oligoprogressive, EGFR-mutant, non-small cell lung cancer (NSCLC) after treatment with osimertinib
Chul Kim, N. Roper, C. Hoang, Laura Wisch +17 more
2018Clinical Trials5 citations
Semantic Scholar
Use of on-therapy ctDNA monitoring in a patient with KIF5B-RET fusion positive advanced non-small cell lung cancer: a case report
V. Yeung, Chul Kim, L. Kiedrowski, Stephen V. Liu +1 more
2022Translational Lung Cancer Research3 citations Open access
Semantic Scholar
Thymic malignancies treated with active scanning proton beam radiation and Monte Carlo planning: early clinical experience
M. McGunigal, M. Margolis, M. Forsthoefel, Tanvee Singh +10 more
2021Acta oncologica3 citations Open access
Semantic Scholar
STK11/TP53 co-mutated non-small cell lung cancer (NSCLC) to display a unique tumor microenvironment (TME) and metabolic profile.
A. Naqash, C. Floudas, A. Maoz, J. Xiu +12 more
20213 citations
Semantic Scholar
Genomic landscape and immune phenotype of malignant pleural mesothelioma.
Meera Patel, A. Elliott, Stephen V. Liu, Chul Kim +10 more
20203 citations
Semantic Scholar
Characterization of ERBB2 alterations in non-small cell lung cancer.
Vijendra Singh, R. Feldman, A. Sukari, Chul Kim +13 more
20203 citations
Semantic Scholar

Frequent co-authors

Invite them to SciRah by sharing their profile.

Stephen V. Liu×23
Invite
Stephen V. Liu — researcher profile on SciRah
G. Giaccone×11
Invite
G. Giaccone — researcher profile on SciRah
A. Rajan×10
Invite
A. Rajan — researcher profile on SciRah
U. Guha×8
Invite
U. Guha — researcher profile on SciRah

×7

Invite

J. Xiu — researcher profile on SciRah

Invite

H. Mamdani — researcher profile on SciRah

Invite

M. Nagasaka — researcher profile on SciRah

Invite

L. Raez — researcher profile on SciRah

Invite

A. Wozniak — researcher profile on SciRah

Invite

H. Borghaei — researcher profile on SciRah

Invite

W. Korn — researcher profile on SciRah

Invite

Y. Baca — researcher profile on SciRah